SCHEMBL22909408

SCHEMBL22909408

COc1ccc(NS(=O)(=O)c2c(N)c(F)c(F)c(F)c2F)cc1F

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.49
HTT P42858 3/20 0.49
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
THRB P10828 2/20 0.49
MAPT P10636 2/20 0.49
PKM P14618 1/20 0.46
TSHR P16473 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
HPGD P15428 1/20 0.44
CA1 P00915 4/20 0.43
CA2 P00918 4/20 0.43
HTR6 P50406 2/20 0.43
KIT P10721 1/20 0.43
ALPL P05186 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Batabulin SCHEMBL29373304 0.90 LMNA (0.54) LMNAHTTALDH1A1MEN1KMT2A
Batabulin SCHEMBL18845 0.90 LMNA (0.54) LMNAHTTALDH1A1MEN1KMT2A
Batabulin SCHEMBL6086887 0.89 LMNA (0.53) LMNAHTTALDH1A1MEN1KMT2A
Batabulin SCHEMBL6089508 0.89 LMNA (0.53) LMNAHTTALDH1A1MEN1KMT2A
SCHEMBL29671221 0.86 LMNA (0.51) LMNAHTTALDH1A1MEN1KMT2A
SCHEMBL22909526 0.86 LMNA (0.51) LMNAHTTALDH1A1MEN1KMT2A
SCHEMBL22909294 0.85 LMNA (0.50) LMNAHTTALDH1A1MEN1KMT2A
SCHEMBL29729041 0.85 LMNA (0.50) LMNAHTTALDH1A1MEN1KMT2A
SCHEMBL22909280 0.84 LMNA (0.49) LMNAHTTALDH1A1MEN1KMT2A
SCHEMBL6676297 0.84 HTR6 (0.53) LMNAHTTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof 2692372 ONTARIO, INC. (CA) 2026-02-24 US disclosed
US-20220281812-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO INC (CA) 2022-09-08 US disclosed
EP-4017843-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 Ontario, Inc. (CA) 2022-06-29 EP disclosed
CN-114502533-A Benzenesulfonamide derivatives and use thereof 2692372安大略公司 2022-05-13 CN disclosed
WO-2021009568-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO, INC. (CA) 2021-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof NR2E1, NR2C2, NR3C1 LMNA 1384/4885HTT 1756/4885ALDH1A1 4335/4885
US-20220281812-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF BCR, ARSA, VHL LMNA 616/4885HTT 380/4885ALDH1A1 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.